SUN PHARMA ADVANCED RESEARCH COMPANY LTD.

Scale -

Revenue is 1879 Rs Cr; Annual Growth is 2518 %; 5 Year CAGR is 99 %; in Bottom Quartile
Ebitda is 1610 Rs Cr; Annual Growth is 601 %; Continuous Growth over 3 years
PBT is -20.67 Rs Cr; Annual Growth is 553 %; in Bottom Quartile
PAT is 1553 Rs Cr; Annual Growth is 553 %; Continuous Growth over 3 years
Quarterly Revenue is 39.92 Rs Cr; Continuous Growth over 3 Quarters; in Bottom Quartile

Quarterly Ebitda is -34 Rs Cr; in Bottom Quartile
Quarterly Profit is -20.78 Rs Cr; in Bottom Quartile

Profitability -

PBDIT Margin is 85.66 %; Annual Growth is 119 %; Continuous Growth over 3 years; in Top Quartile
PAT Margin is 82.65 %; Annual Growth is 117 %; Continuous Growth over 3 years; in Top Quartile

Quarterly Ebitda Margin is -85 %; in Bottom Quartile
Quarterly Profit margin is -52 %; in Bottom Quartile

Return -

ROA is 71.54 %; Annual Growth is 170 %; in Top Quartile
Asset Turnover is 150 %; Annual Growth is 782 %; Continuous Growth over 3 years; in Top Quartile
ROE is 116.01 %; Continuous Growth over 3 years; in Top Quartile
ROCE is 112.89 %; in Top Quartile; Annual Decline is -87 %

Efficiency -

Current Ratio is 2.47; Annual Growth is 3429 %
Quick Ratio is 2.47; Annual Growth is 3429 %; in Top Quartile
Operating cash flow is -239 Rs Cr; Annual Growth is 34 %; Continuous Growth over 3 years; in Bottom Quartile

Inventory Turnover Ratio is 0; in Bottom Quartile

Solvancy -

Long term Debt is 0 Rs Cr; Annual Decline is -100 %

Debt/Equity is 0.42; Annual Growth is 135 %; in Top Quartile
Total Debt is 556 Rs Cr; Annual Growth is 115 %; Continuous Growth over 3 years; 5 Year CAGR is 2132 %

Quality -

Current Tax/PAT is 0 %; in Bottom Quartile; Annual Growth is 86 %; Continuous Growth over 3 years
Other Expenses/Total Expenses is 14 %; in Bottom Quartile; Annual Growth is 32 %

Operating cashflow/ebitda is -15 %; Annual Decline is -113 %; Continuous Decline over 3 years; in Bottom Quartile
Operating cashflow/PAT is -15 %; Annual Decline is -115 %; Continuous Decline over 3 years; in Bottom Quartile

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem

Sector

Major Subsidiaries/Associates

Key Clients

Products

Products

Product details

Operations

Capacity/ Production

Key Facilities

Key Certifications

Raw materials

Search:

Sun Pharma Advanced Research Company Stock Price Forecast. Should You Buy SPARC.NS?

Past/current

SPARC appoints Anil Raghavan as Managing Director and CEO

Past/current

SPARC NSE Demat Confirmation Certificate Q2 FY27 Filing

Past/current

Sun Pharma Advanced Research Wins CESTAT Ruling, Secures Rs 27.51 Cr CENVAT Refund

Past/current

CESTAT upholds ?2,751 lakh CENVAT credit refund for Sun Pharma Advanced Research

Past/current

SPARC CESTAT Ruling: Rs 2,751 Lakh CENVAT Refund Upheld

Past/current

Sun Pharma Advanced Research wins ?28 crore CENVAT credit refund case in CESTAT

Past/current